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Behcet’s Disease
Karina Julian and Bahram Bodaghi
Abstract
Defined as a systemic vasculitis developing in a particular genetic back-
ground, uveitis is one of the hallmarks to diagnose Behcet’s disease and also one 
of the important clinical criteria to start systemic treatment. Isolated anterior 
non granulomatous uveitis with hypopyon, even though a classic clinical picture,  
actually develops in a minority of cases. In most patients, uveitis is posterior, 
associated to small vessel occlusive retinal vasculitis, carrying a high risk of per-
manent retinal damage and subsequent severe visual loss. The guarded natural 
prognosis of the disease has positively changed in the last decennials with the 
introduction of biologic immunosuppressant agents in the field of uveitis. Vision 
can be preserved in most cases provided a prompt early diagnosis and adequate 
therapy. The potential role of oral bacteria as a triggering factor for autoinflam-
mation in predisposed hosts is interesting, opening the door to prevention in this 
still not well-understood severe uveitis.
Keywords: hypopyon uveitis, occlusive vasculitis, retinitis, retinal atrophy, 
immunosuppressants
1. Introduction
Named after the Turkish ophthalmologist, Hulusi Behcet (who described in 1937 
the classic triad of oral aphthosis, genital ulcers, and hypopyon uveitis) [1], Behcet’s 
disease (BD) is a systemic relapsing obliterative vasculitis, affecting arteries, veins, 
and mainly capillaries. Even though almost all organs can eventually be involved, 
the compromise of the central nervous system (CNS) and eye makes the disease’s 
prognosis guarded and usually urges to start proper treatment.
There is no specific test to diagnose Behcet’s disease: by definition, its diag-
nosis is a clinical one. In 1990, the International Study Group for Behcet’s disease 
established a set of diagnostic criteria in an attempt to unify the five different ones 
used by that time [2]. They required the presence of oral ulcerations plus any two 
of genital ulcerations, typical defined eye lesions, typical defined skin lesions or a 
positive pathergy test.
Far from being solved, the debate on the diagnostic criteria is still active, and 
many other sets have been proposed. Among them, the Behcet’s Disease Research 
Committee of Japan defines the diagnosis as complete or incomplete upon the pres-
ence of major and minor symptoms (Table 1) [3]. The Dilsen criteria (revised in 
2000) seems more suitable to the European patients suffering from Behcet’s disease 
(Table 2) [4, 5].
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2. Clinical picture
2.1 Non-ocular disease
Almost every organ and system can eventually be affected by this severe vascu-
litis. Painful, recurrent oral and genital ulcers are so frequent that their presence is 
part of the diagnostic criteria [6]. Other skin manifestations are papulopustules, 
Three out of the five following criteria are required to diagnose Behcet’s disease
1. Recurrent oral ulcers
2. Recurrent genital ulcers
3. Skin lesions
4. Eye lesions
5. Thrombophlebitis
(+) Skin pathergy test
Always exclude other causative factors
Table 2. 
Behcet’s disease: the Dilsen criteria.
1. Major symptoms
(a) Recurrent aphthous oral ulcers
(b) Skin lesions: erythema nodosum-like lesions, thrombophlebitis, folliculitis, and cutaneous hypersensitivity
(c) Ocular symptoms: iridocyclitis, retinitis, and sequelae of uveitis
(d) Genital ulcers
2. Minor symptoms
(a) Arthritis
(b) Intestinal Behcet’s disease
(c) Epididymitis
(d)  Vascular lesions
(e) Neurologic lesions
3. Examination
Pathergy test
4. Diagnosis
A. Complete type: all four major symptoms present
B. Incomplete type:
• Three major symptoms present
• Two major and two minor symptoms present
• Ocular symptoms and one other major symptom present
• Ocular symptoms and two minor symptoms present
Table 1. 
Behcet’s Disease Research Committee of Japan: diagnostic criteria.
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acneiform dermatitis, and erythema nodosum [7]. Arthritis is also a common mani-
festation of the disease [8]. Gastrointestinal involvement affects around 3–30% of 
cases with symptoms overlapping inflammatory bowel disease [9]. Central nervous 
system (CNS) involvement can touch almost 31% of patients and makes the progno-
sis guarded [10]. Venous thrombosis and arterial aneurysms are present in around 
25% of cases [11].
2.2 Ocular disease
The classic clinical picture is the one of recurrent, bilateral, non-granulomatous 
posterior or panuveitis with retinal vasculitis. This is the case for almost 80% of 
patients, while in around 10% disease manifests as anterior, non-granulomatous 
uveitis with hypopyon and eventually synechiae (Figure 1) [12].
Disease seems to be more severe in males, and ocular pain, redness, photopho-
bia, and blurred vision are almost always present.
Retinitis is also a classic and sight-threatening manifestation of posterior seg-
ment involvement, leading most of the time to retinal atrophy. Indeed, Behcet’s 
disease is one of the differential diagnoses of macular atrophy related to uveitis 
(Figure 2) [13].
Retinal vasculitis is the hallmark of the disease, it is obliterative in nature, it 
affects both arteries and veins, and, most importantly, it involves the capillaries [14].
Behcet’s disease is mainly a capillaropathy, being fluorescein angiography (FA) 
essential to its proper diagnosis and management. FA will better delineate areas of 
non-perfusion (Figure 3), capillary leakage (Figure 4), and vascular remodeling. 
The “fern-leaf”-shaped leakage pattern from capillaries, even though not pathogno-
monic, is highly evocative of BD (Figure 5).
Given the highly vascularized nature of choroidal tissue, it is not surprising to 
see choroidal involvement during active disease. Indocyanine green angiography 
(ICGA) shows irregular filling of the choriocapillaris, choroidal filling defects, and 
dye leakage from choroidal vessels [15]. Enhanced depth imaging optical coherence 
tomography (EDI-OCT) shows increased subfoveal choroidal thickness even in eyes 
without evident uveitis activity, making this finding a possible indicator of subclini-
cal ocular inflammation in patients with BD [16].
Optic neuropathy (ON), although considered a rare manifestation of Behcet´s 
disease, might actually be overshadowed by uveitis’ complications. It can appear 
during the course of already known BD (and should be considered as part of the 
neuro-BD disease spectrum), or it can even be the first manifestation of the disease 
(BD should then be kept in mind as a differential diagnosis of optic neuropathy 
Figure 1. 
Hypopyon and nasal synechiae in the left eye of a young patient suffering from acute reactivation of anterior 
uveitis related to Behcet’s disease.
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Figure 3. 
Late-frame fluorescein angiography showing extensive peripheral areas of retinal non-perfusion affecting the 
inferior temporal area of the right eye.
Figure 4. 
Early frame fluorescein angiography of the right eye of a patient suffering from Behcet’s disease 
retinal vasculitis. Areas of capillary leakage are present as well as peripheral ischemia and optic disc 
hyperfluorescence.
Figure 2. 
Horizontal OCT scan from the right eye of a patient with advanced Behcet’s disease posterior uveitis. 
Generalized retinal atrophy and retinal pigment hypertrophy are seen.
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in regions where its prevalence is high) [17]. The prognosis of BD-associated ON 
seems not to be as poor as the one of BD uveitis, with excellent response to the 
combination of corticosteroids and immunosuppressants and recovery as the rule 
[18, 19]. However, the use of cyclosporine should be avoided in these cases since it 
could promote the development of neurologic involvement [20].
3. Etiology and pathogenesis
Despite years of research, BD remains idiopathic. Even though there are sporadic 
cases all around the world, disease is more prevalent along the ancient silk route and 
in countries located between 30 and 45 north latitude through the Mediterranean 
Basin, the Middle East, and Far East regions such as China and Japan [21]. This 
particular geographic distribution points toward a genetic predisposing factor. The 
high frequency of HLA-B51 among a wide range of affected ethnic populations 
highlights the importance of a special genetic background: even though not consid-
ered as part of the diagnostic criteria, the positivity of HLA-B51 increases the risk of 
BD in around six times [22].
Besides the classic and well-known predisposition to BD associated with HLA-
B51 positivity, new insights on disease’s pathogenesis came out from genome-wide 
association studies (GWAS). The disruption of different biological pathways 
might determine the intrinsic biological process in multifactorial diseases, as 
BD. Six biologic pathways have been recently identified as possible mechanisms 
in the pathogenesis of BD:focal adhesion pathway, MAPK (mitogen-activated 
protein kinase) signaling, TGF (transforming growth factor) beta signaling, 
ECM-receptor interaction, complement and coagulation cascades and proteasome 
pathways [23].
Then, on this special genetic background, environmental factors might play a 
role as triggers for disease development. Infectious agents have been postulated 
as these triggering factors. Recently, a relationship between periodontal disease 
and specific polymorphisms of interleukin (IL)-1alpha and (IL)-1beta in Turkish 
patients with BD was reported, making periodontitis-induced autoinflammatory 
response a candidate for the development or severity of BD via IL-1 gene alteration 
[24]. Improvement of oral health among this high-risk population might affect BD 
course, leading to a better prognosis [25].
Figure 5. 
Late-frame fluorescein angiography of the right and left eye from a patient suffering from Behcet’s disease 
associated with retinal vasculitis. Typical “fern-leaf” pattern of capillary leakage is present.
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Neutrophils’ activation plays a predominant role in BD; this is evidenced 
through the positivity of pathergy test, one of the diagnostic criteria for the disease 
[2, 26]. The activation of the innate immune system against environmental and/
or autoantigens in this particular genetic background is then perpetuated by the 
adaptive immune system [27].
4. Diagnosis and differential diagnosis
As it was already stated, diagnosis is clinical and based on the presence of differ-
ent combinations of symptoms and signs. In the acute attack, patients usually show 
raised inflammatory acute reactants (sedimentation rate and C-reactive protein) 
and high levels of white blood cells, mainly neutrophils [28, 29].
HLA-B51 is positive in around 50–70% of cases even though not necessary for 
the diagnosis [22, 30].
Differential diagnosis of hypopyon uveitis encompasses HLA-B27 associated, 
endogenous/exogenous endophthalmitis, toxic anterior segment syndrome (TASS) 
after cataract surgery, and masquerade syndromes [31–35]. BD-associated retinal 
vasculitis is unique in its predilection for capillaries but a similar picture can even-
tually be found in cases of HLA-B27 posterior uveitis with retinal vasculitis [36–39].
5. Treatment
Topical treatment is reserved for the minority of cases in which anterior uveitis 
is the only ocular disease manifestation. Prednisolone acetate with or without 
cyclopentolate is usually enough to stop episodes of anterior non-granulomatous 
uveitis. However, if these attacks are frequent or inflammatory quiescence requires 
more than three drops per day of prednisolone acetate for long periods, systemic 
treatment should be initiated.
The majority of cases presenting with posterior uveitis will require systemic 
treatment to control the sight-threatening manifestations of the disease.
High-dose systemic corticosteroids (1 g intravenous of Solu-Medrol or 1 mg/kg/
day of oral prednisone) are useful in severe acute inflammatory attacks. However, 
they should not be administered alone given the high risk of flare up while tapering 
and the side effect profile of high doses [40].
Azathioprine and cyclosporine have both shown to be effective in BD’s uveitis 
in two different randomized clinical trials (RCT) [41–43]. In many cases, a single 
agent is not enough to control uveitis, and a combination of them is administered. 
Drugs are usually well tolerated in long term, providing the proper check of their 
own side effects’ profile is performed (liver toxicity for azathioprine, renal toxic-
ity for cyclosporine). The likelihood of patients on cyclosporine to develop CNS 
complications should be kept in mind, and the drug is not recommended in the 
management of BD’s associated optic neuropathy [44].
High levels of tumor necrosis factor (TNF) alpha are present in BD’s uveitis [45]. 
The blockage of this inflammatory pathway is therefore a very effective approach 
to disease control. Infliximab (a chimeric monoclonal antibody against TNF alpha) 
and adalimumab (a fully humanized monoclonal antibody) are both widely used 
in the treatment of BD-associated posterior uveitis with high rates of success [46]. 
Adalimumab has the advantage of subcutaneous administration, theoretically 
improving patients’ quality of life [47].
Other anti-TNF alpha molecules, such as certolizumab pegol and golimumab, 
have also shown positive results in small case series of BD’s uveitis [48, 49].
7© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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Interferon alpha-2ª is a very effective biologic treatment for BD’s associated 
posterior uveitis [50]. Subcutaneously administered, it has rapid positive effect 
and also long relapse-free period making prophylactic maintenance treatment 
unnecessary [51, 52]. Drug is administered as a monotherapy after discontinuation 
of all previous immunosuppressive drugs (including corticosteroids). However, the 
associated flu-like syndrome limits the use of this important agent in the manage-
ment of BD’s uveitis.
Cytotoxic agents (chlorambucil and cyclophosphamide) were in the past the 
drug of choice for this severe form of uveitis [53, 54]. Nowadays, however, given the 
more specific and less toxic agents available, they are only used in those settings
Intravitreal steroids (either triamcinolone acetonide, fluocinolone, or dexameth-
asone implant) are adjuvant rescue treatment in recalcitrant cases not responding 
to systemic medication or whenever systemic medication is contraindicated [55]. 
Their effect is always transitory and associated with the risk of local complications 
(mainly cataract and glaucoma).
6. Prognosis
Visual prognosis is directly related to anatomical location of inflammation and 
rapid introduction of proper treatment. The minority of cases manifesting only by 
anterior uveitis usually shows excellent visual prognosis. Posterior uveitis, however, 
might be sight-threatening even if only one acute attack involves the macula. The 
development of modern biologic agents has positively changed the natural guarded 
prognosis of this disease even though there is still a low proportion of cases that will 
not respond to different combinations of treatment.
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